<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852407</url>
  </required_header>
  <id_info>
    <org_study_id>BHS-TC14</org_study_id>
    <secondary_id>2017-000824-91</secondary_id>
    <nct_id>NCT03852407</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning</brief_title>
  <acronym>HLA</acronym>
  <official_title>Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belgian Hematological Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The&#xD;
      hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from&#xD;
      30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized&#xD;
      study).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, open-label, phase II study pick-a-winner study,&#xD;
      comparing 2 conditioning regimens. A total of 114 eligible patients with HLA-matched donors&#xD;
      will be randomized 1:1 between the FM-PTCy arm and the FM-ATG arm, with stratification for&#xD;
      donor type (related or unrelated). The recruitment period is 3 years with a 5-year follow-up&#xD;
      plus a 10-year additional long-term follow-up (for GVHD status, disease status, second&#xD;
      malignancy and QOL). The whole study will be completed within 18 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2038</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2033</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Current GVHD-free, relapse-free survival (cGRFS)</measure>
    <time_frame>15 years (the primary endpoint will be first assessed after 191 events have been reached)</time_frame>
    <description>To assess the current GVHD-free, relapse-free survival (cGRFS) for patients in the 2 arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cGRFS according donor</measure>
    <time_frame>15 years</time_frame>
    <description>To assess cGRFS for patients conditioned with FM-PTCy or FM-ATG separately in those transplanted with a related or an unrelated donor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse/progression rate</measure>
    <time_frame>15 years</time_frame>
    <description>To assess the relapse/progression rate for patients conditioned with FM-PTCy or FM-ATG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate aGVHD</measure>
    <time_frame>6 months</time_frame>
    <description>To assess rate of grade II-IV and III-IV acute GVHD (Graft-versus-host disease) in patients conditioned with FM or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate cGVHD</measure>
    <time_frame>24 months</time_frame>
    <description>To assess rate of grade of moderate-severe chronic GVHD in patients conditioned with FM or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Nonrelapse Mortality (NRM)</measure>
    <time_frame>15 years</time_frame>
    <description>To assess rate of Nonrelapse Mortality in patients conditioned with FM-PTCy or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Leukemia Free Survival (LFS)</measure>
    <time_frame>15 years</time_frame>
    <description>To assess rate of Leukemia Free Survival in patients conditioned with FM-PTCy or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Overall Survival (OS)</measure>
    <time_frame>15 years</time_frame>
    <description>To assess rate of Overall Survival in patients conditioned with FM-PTCy or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive</measure>
    <time_frame>15 years</time_frame>
    <description>To assess the proportion of patients alive without active disease and without systemic immunosuppression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hematopoietic engraftment</measure>
    <time_frame>2 years</time_frame>
    <description>To assess hematopoietic (whole blood and T cell chimerism) engraftment in the 2 arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of immunologic reconstitution</measure>
    <time_frame>5 years</time_frame>
    <description>To assess the quality of immunologic reconstitution in the 2 arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Timing of immunologic reconstitution</measure>
    <time_frame>5 years</time_frame>
    <description>To assess the timing (days) of immunologic reconstitution in the 2 arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of bacterial infections</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the incidences of bacterial infections (number of episode, site, grade) in the 2 arms, in the whole group of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of fungal infections</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the incidences of fungal infections (number of episode, site, grade) in the 2 arms, in the whole group of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of viral infections</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the incidences of viral infections (number of episode, site, grade) in the 2 arms, in the whole group of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess Thymoglobulin (ATG) Pharmacokinetic</measure>
    <time_frame>10 days</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with cGRFS</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with cGRFS</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with NRM</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with NRM</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with OS</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with OS</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with Relapse/progression</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with Relapse/progression</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with Infections</measure>
    <time_frame>1 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with Infections</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with immunologic reconstitution</measure>
    <time_frame>5 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with immunologic reconstitution (CD4 and NAIVE T cells counts)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Myeloid Leukemia in Remission</condition>
  <condition>Myeloproliferative Syndrome</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Acute Lymphoid Leukemia in Remission</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Lymphoid Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Fludarabine-Melphalan-Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)</description>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>100mg/m² on day -2</description>
    <arm_group_label>Fludarabine-Melphalan-Cyclophosphamide</arm_group_label>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
    <other_name>alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m² on days -6, -5, -4, -3, and -2</description>
    <arm_group_label>Fludarabine-Melphalan-Cyclophosphamide</arm_group_label>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamid</intervention_name>
    <description>50 mg/kg on days +3 and +4.</description>
    <arm_group_label>Fludarabine-Melphalan-Cyclophosphamide</arm_group_label>
    <other_name>PTCy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients V.1.1. Diseases&#xD;
&#xD;
        Hematological malignancies confirmed histologically:&#xD;
&#xD;
          -  AML in morphological CR or not in morphological CR but not rapidly progressing (i.e.&#xD;
             no need to give treatments such as hydroxyurea to maintain WBC count &lt; 10 000&#xD;
             x109/mL);&#xD;
&#xD;
          -  MDS;&#xD;
&#xD;
          -  CML in CP or AP;&#xD;
&#xD;
          -  MPD not in blast crisis,&#xD;
&#xD;
          -  MDS/MPD overlap,&#xD;
&#xD;
          -  ALL in CR;&#xD;
&#xD;
          -  Multiple myeloma;&#xD;
&#xD;
          -  CLL;&#xD;
&#xD;
          -  Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);&#xD;
&#xD;
          -  Hodgkin's disease with chemosensitive disease or responding to checkpoint inhibitors.&#xD;
&#xD;
             * Clinical situations&#xD;
&#xD;
             • Theoretical indication for a standard allo-transplant, but not feasible because:&#xD;
&#xD;
          -  Age &gt; 50 yrs;&#xD;
&#xD;
          -  Unacceptable end organ performance;&#xD;
&#xD;
          -  The physician's decision;&#xD;
&#xD;
          -  The patient's decision&#xD;
&#xD;
               -  Underlying 'lower risk' disease, for which Reduced Intensity Conditioning is&#xD;
                  preferred (eg CLL, MCL)&#xD;
&#xD;
                  * Other inclusion criteria&#xD;
&#xD;
               -  Male or female; fertile patients must use a reliable contraception method;&#xD;
&#xD;
               -  Age 18-75 yrs (children of any age are not allowed in the protocol);&#xD;
&#xD;
               -  Informed consent given by patient or his/her guardian if indicated.&#xD;
&#xD;
        Donors&#xD;
&#xD;
          -  Male or female;&#xD;
&#xD;
          -  Any age;&#xD;
&#xD;
          -  Human Leukocyte Antigen (HLA)-identical sibling donor or 10 of 10 (HLA-A, -B, -C,&#xD;
             -DRB1, and -DQB1) HLA allele matched unrelated donor;&#xD;
&#xD;
          -  Weight &gt; 15 Kg (because of leukapheresis);&#xD;
&#xD;
          -  Fulfills criteria for allogeneic Peripheral Blood Stem Cell (PBSC) donation according&#xD;
             to standard procedures;&#xD;
&#xD;
          -  Informed consent given by donor or his/her guardian if indicated, as per donor center&#xD;
             standard procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Any condition not fulfilling inclusion criteria;&#xD;
&#xD;
          -  Human Immunodeficiency Virus positive;&#xD;
&#xD;
          -  Non-hematological malignancy(ies) (except non-melanoma skin cancer) active &lt; 3 years&#xD;
             before Hematopoietic Cell Transplantation (HCT).&#xD;
&#xD;
          -  Life expectancy severely limited by disease other than malignancy;&#xD;
&#xD;
          -  Central Nervous System involvement with disease refractory to intrathecal&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Terminal organ failure, except for renal failure (dialysis acceptable)&#xD;
&#xD;
               1. Cardiac: Symptomatic coronary artery disease; ejection fraction &lt;40%;&#xD;
                  uncontrolled arrhythmia, uncontrolled hypertension;&#xD;
&#xD;
               2. Pulmonary: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)&lt; 40% and/or&#xD;
                  receiving supplementary continuous oxygen, Forced Expiratory Volume in 1 Second&#xD;
                  (FEV1)&lt; 40%;&#xD;
&#xD;
               3. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal&#xD;
                  hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding&#xD;
                  esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic&#xD;
                  dysfunction evinced by prolongation of the prothrombin time, ascites related to&#xD;
                  portal hypertension, bacterial or fungal liver abscess, biliary obstruction,&#xD;
                  chronic viral hepatitis with total serum bilirubin &gt;3 mg/dL, and symptomatic&#xD;
                  biliary disease;&#xD;
&#xD;
          -  Uncontrolled infection;&#xD;
&#xD;
          -  Karnofsky Performance Score &lt;70%;&#xD;
&#xD;
          -  Patient is a fertile man or woman who is unwilling to use contraceptive techniques&#xD;
             during and for 12 months following treatment;&#xD;
&#xD;
          -  Patient is a female who is pregnant or breastfeeding;&#xD;
&#xD;
          -  Any condition precluding the use of melphalan or Thymoglobulin;&#xD;
&#xD;
        Donors&#xD;
&#xD;
          -  Any condition not fulfilling inclusion criteria;&#xD;
&#xD;
          -  Unable to undergo leukapheresis because of poor vein access or other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric Baron, MD,Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Liege</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric Baron, MD,Ph</last_name>
    <phone>+32 4 366 72 01</phone>
    <phone_ext>0032497121806</phone_ext>
    <email>F.Baron@uliege.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitri Breems, MD PhD</last_name>
      <email>dimitri.Breems@zna.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Selleslag, MD, PhD</last_name>
      <email>dominik.selleslag@AZsintjan.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IJ Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Lewalle, MD PhD</last_name>
      <email>philippe.lewalle@bordet.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann De Becker, MD PhD</last_name>
      <email>ann.debecker@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Rik Schots, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Poiré, MD</last_name>
      <email>xavier.poire@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tessa Kerre, MD PhD</last_name>
      <email>t.Kerre@UGent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Maertens, MD PhD</last_name>
      <email>johan.maertens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Hélène Schoemans, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Baron, MD, PhD</last_name>
      <phone>+3243667201</phone>
      <phone_ext>+3243667201</phone_ext>
      <email>F.Baron@uliege.be</email>
    </contact>
    <contact_backup>
      <last_name>Yves Beguin, MD, PhD</last_name>
      <phone>+3243667201</phone>
      <phone_ext>+3243667201</phone_ext>
      <email>yves.beguin@chuliege.be</email>
    </contact_backup>
    <investigator>
      <last_name>Evelyne Willems, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Servais, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta Roeselare</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dries Deeren, MD</last_name>
      <email>dries.deeren@AZdelta.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Graux, MD PhD</last_name>
      <email>carlos.graux@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Frédéric Baron</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hematological malignancies</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Progression free survival</keyword>
  <keyword>Allogeneic hematopoeitic cell transplantation</keyword>
  <keyword>HLA-matched donor</keyword>
  <keyword>reduced intensity conditioning</keyword>
  <keyword>Overall survival</keyword>
  <keyword>ATG PK</keyword>
  <keyword>Immunosuppressive regimen</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

